DK CRUSH Is Still The Best Option

Courtesy of Dr. Carlos Fava.

When it comes to severe unprotected left main distal bifurcation lesions, surgery continues to be the preferred treatment option. However, due to the growing number of patients that cannot receive surgery, left main PCI has significantly advanced, and though the strategy in this scenario remains controversial, double kissing crush stenting (DK CRUSH) was shown superior to provisional stenting (PS) at one-year follow-up (though there is no data beyond this period).

DKCRUSH-V: El tronco de la coronaria izquierda no es una bifurcación más

The DKCRUSH-V trial randomized 482 patients with severe left main bifurcation lesion (1.1.1 or 0.1.1). 242 received PS and 204 received two stents with DK CRUSH.

They all received antiaggregation with AAS and clopidogrel for at least 12 months.

Both groups were well balanced, mean age was 65, 27.2% were diabetic, most presented unstable angina, 21% had prior MI, 88% multivessel disease, 37% SYNTAX score >32.


Read also: STEMI in Coronary Dissections. When Should We Do It and What Are Its Outcomes?


At 3-year follow-up, TLF occurred in 16.9% of patients undergoing PS and in 8.3% of patients receiving DK CRUSH (p=0.005). Target vessel MI was 5.1% vs. 1.7% (p=0.01), TLR was 10.3% vs. 5% (p=0.002) and definite or probable thrombosis was also higher in the group receiving PS (4.1% vs. 0.4% p=0.006).

In patients presenting SYNTAX >32 or NERS II ≥19, PS was associated to higher stent thrombosis, TLF, TLR and TV MI. It was not the case of those presenting less complex anatomy.

Conclusion

Provisional stenting in unprotected left main lesions was associated to a significant increase in stent thrombosis at 3 years. We need more randomized studies to confirm the benefit of DK CRUSH in complex unprotected left main lesions.

Courtesy of Dr. Carlos Fava.

Original title: Three-Year Outcomes of the DKCRUSH-V Trial Comparing DK Crush With Provisional Stenting for Left Main Bifurcation Lesions.

Reference: Xiang Chen, et al. J Am Coll Cardiol Intv 2019; Article in Press.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....